Organization | Academia Sinica, Taiwan

Academia Sinica, Taiwan Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: Nangang China (1928)

Organization Overview

First Clinical Trial

2009

NCT02065388

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Academia Sinica, Taiwan

Active Ingredients

Drugs in Phase 4 Trials (2)

atomoxetine (strattera) (1 trial)

methylphenidate (ritalin) (1 trial)

Drugs in Phase 3 Trials (1)

warfarin (coumadin) (1 trial)

Drugs in Phase 2 Trials (2)

bone marrow derived mononuclear cells (1 trial)

hyaluronic acid (1 trial)

Drugs in Other Trials (10)

celery (1 trial)

citric acid (1 trial)

fish oil (Omegavan) (1 trial)

hepatitis b vaccine (recombinant) (Recombivax) (1 trial)

magnesium citrate (1 trial)

onion (1 trial)

spinach (1 trial)

sucralose (1 trial)

vegetable protein (1 trial)

wheat (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Arterial Occlusive Diseases (Phase 2)

Atrial Fibrillation (Phase 3)

Atrial Flutter (Phase 3)

Ischemia (Phase 2)

Thrombosis (Phase 3)

Venous Thrombosis (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial APIs: 15